Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FD&C YELLOW NO. 5: FDA FINAL RULE APPROVING DYE's PERMANENT LISTING

Executive Summary

FD&C YELLOW NO. 5: FDA FINAL RULE APPROVING DYE's PERMANENT LISTING as safe for use in cosmetics and externally applied drugs is effective retroactive to October, according to a notice due to be published in the July 7 Federal Register. The color additive already is approved for food and ingested drugs. A stay was placed on the rule permitting the dye's permanent listing because FDA received objections to it from industry and consumer groups and was required by law to review them before the final rule went into effect. Published Sept. 5, 1985, the final rule was to have been effective 30 days afterward. While the agency reviewed the objections, FDA extended the closing date of Yellow 5's provisional listing four times. With the stay on the rule now lifted, the original effective date of Oct. 7, 1985 is "confirmed for all portions of the final rule except the description of the manufacturing process modified in this notice," the Federal Register document states. Termination of the stay on the final rule approving Yellow 5 for cosmetic and external drug use actually goes into effect August 7. Of the three objections received and evaluated, FDA dismissed those of the Certified Chemical Manufacturers' Association (CCMA) and Public Citizen's Health Research Group (HRG) as "without merit." CCMA's objections centered on the final rule's specifications for six impurities found in the dye, the analytical methodology used by the agency to determine its safety and the exclusion of the additive's lakes from the permanent listing. HRG's complaints concerned lowered sulfonated forms of Yellow 5, its known potential to cause allergic reactions in humans and mutagenicity in lab animals. FDA concluded that the third objection, one from dye manufacturer Hilton-Davis regarding the general description of the dye's permitted manufacturing processes, "is correct" and the agency is modifying the section (21 CFR 74.2705) accordingly. In a separate same-day notice, FDA revised the identity and specifications for FD&C Yellow 5 for use in food and ingested drugs The agency stated that during its recent review of Yellow 5 in externally applied drugs and cosmetics, it determined "that continued safe use of the additive would require the adoption of a new identity and more extensive specifications for the color additive."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel